Companies › Regor Pharmaceuticals
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RGT-419B unclear - likely a kinase inhibitor based on context of CDK4/6i resistant breast cancer | – | Phase 1 | Breast Cancer | Dec 2026 |
| RGT-490 PIK3CA inhibitor | PIK3CA | Phase 1 | Breast Cancer | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05304962 | RGT-419B | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT06299124 | RGT-419B | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT07524322 | RGT-490 | Phase 1 | Breast Cancer | Oncology | Apr 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.